Modern al(radio)chemistry to diagnose and treat cancer

Résumé (conférence en anglais) |The use of radionuclides has become common in the diagnosis and therapy of cancer. Targeted radionuclide diagnostics and therapy based on the combination of appropriate radionuclides with selective delivery systems (e.g. antibodies, peptides etc.) maximizes the precision of the imaging as well as minimizes the damage of healthy tissues during therapy. The application and objective will define the appropriate therapeutic radionuclides, emitting alpha, beta- particles or auger electrons, as well as the appropriate bifunctional chelator systems to effectively attach these radionuclides (e.g. radiometals) to biomolecules.
TRIUMF provides a unique infrastructure for the production of medical radionuclides with protons for imaging and therapy, including well-established imaging radionuclides e.g. ¹⁸F and ¹¹C, as well as several imaging radiometals including ⁶⁸Ga,⁴⁴Sc, ⁸⁶Y and ⁸⁹Zr and therapeutic radionuclides such as ¹¹⁹Sb, ¹⁹⁷m+gHg, ¹⁰³Pd. Besides, the TR-13 Life Sciences Division utilized other TRIUMF facilities, including ISAC (production of ^209/211At, ^225Ra/225Ac, ²²⁶Ac, ^149/155Tb, ¹⁶⁵Er), Isotopes Production Facility (IPF) for spallation reaction on thorium target for production of emerging therapeutic radionuclides (e.g. ²²⁵Ac). The status of utilization of these facilities will be presented as well as potential future production capabilities, including ARIEL proton and electron beamlines and IAMI will be discussed.

À propos de la présentatrice: Valery Radchenko est chercheur au Centre canadien d'accélération des particules (TRIUMF) et professeur auxiliaire au département de chimie de l‘Université de Colombie-Britannique. Ses recherches portent principalement sur la production et l'application de radionucléides thérapeutiques pour la thérapie radionucléide ciblée (TRT).

Conférence présentée au local X9-2999 ou en ligne 

Téchargez l'affiche